From Cultivated Meat to Chocolate: Rethinking Cellular Agriculture Scale-Up – Part 2
Our food systems face a monumental challenge: by 2050, the global population could reach 10 billion, demanding at least 60% more food than we produce today.
From Cultivated Meat to Chocolate: Rethinking Cellular Agriculture Scale-Up – Part 1
What if your daily chocolate or coffee could be brewed without farms—or deforestation—but straight from a bioreactor?
From Batch to Continuous: Building Innovation Culture in Conservative Biotech Environments – Part 2
The biotech community is in continuous transformation. The landscape we navigate today will be dramatically different a decade from now, just as it was a decade ago.
From Batch to Continuous: Building Innovation Culture in Conservative Biotech Environments – Part 1
What does it take to build an innovation culture in one of the world’s most careful—and consequential—industries?
Cryogenic Infrared Ion Spectroscopy: From Mass Spec Limitations to Molecular Precision – Part 2
Imagine unlocking a biological sample and, instead of peering under the usual “streetlight” of targeted analysis, being able to illuminate the entire landscape of metabolites, glycans, and unknown impurities.
Cryogenic Infrared Ion Spectroscopy: From Mass Spec Limitations to Molecular Precision – Part 1
The identification and characterization of biological molecules is central to the biotech industry, particularly in drug development, bioprocess optimization, and advanced analytics.
Mastering CRO Selection: Essential Questions for CMC Analytical Development – Part 2
Cell and gene therapies have redefined what’s possible in modern medicine, but their road to market is anything but straightforward.
Mastering CRO Selection: Essential Questions for CMC Analytical Development – Part 1
Many biotech teams are sprinting to create breakthrough therapies, but often encounter the intricate and numerous challenges of CMC development.
Mastering ADC Development: CDMO Strategies for Analytics and Scale-Up – Part 2
What happens when the charging elephant of biotech—antibody-drug conjugates (ADCs)—meets the organizational complexity of a 300-strong analytical powerhouse?
Mastering ADC Development: CDMO Strategies for Analytics and Scale-Up – Part 1
Antibody-drug conjugates (ADCs) are generating serious buzz in biotech corridors, offering a precision-guided missile against cancer while minimizing collateral damage.